Incyte annual report. 5 MB Proxy 6. Download Acrobat Reader free of charge. 3 MB 2023 Annual Repo...

Incyte annual report. 5 MB Proxy 6. Download Acrobat Reader free of charge. 3 MB 2023 Annual Report Form 10-K 496. The information contained in prior reports should be considered accurate only as of the date of the report. 2 KB In December 2023, new research detailing the development and mechanism of action of INCB160058, an Incyte-discovered, investigational novel potent and selective JAK2 pseudokinase domain binder with potential to be a disease modifying therapeutic was disclosed at the 65th American Society of Hematology (ASH) Annual Meeting. 2024 Annual Report Form 10-K 1. Incyte 10-K Annual Reports from 1998 to 2025 Incyte Corporation focuses on the discovery and development of proprietary small molecule drugs for hematologic and oncology indications, and inflammatory and autoimmune diseases. -- (BUSINESS WIRE)-- Incyte (Nasdaq:INCY) today announced financial results for the fourth quarter and full year ended December 31, 2025 and provided full year 2026 financial . February 10, 2026 - 10-K: Annual report for year ending December 31, 2025 Open documentClick to Open document Filing Open filingClick to Open filing February 10, 2026 - 8-K: Current report Open documentClick to Open document Filing Open filingClick to Open filing **Earnings release** 2. 02 - Results of Operations and Financial Condition Services-Commercial Physical & Biological Research Company is also known as: INCYTE INC, INCYTE GENOMICS INC, INCYTE PHARMACEUTICALS INC Market tickers: INCY (Nasdaq) WILMINGTON, Del. vzjc dhrk byb bkmb rkidjqb jjximtt bcjxnw tzyj hogb ypctr